All In Biotech

Drug Trial Radar · NCT07790159

Budesonide/Formoterol Inhalation Powder in Adults With Asthma

A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Budesonide/Formoterol Inhalation Powder in Adults With Asthma

Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 338 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

338

Actual

Start

Feb 21, 2024

Primary completion

Sep 27, 2024

Study completion Nov 7, 2024

Sponsor

Sponsor type
Industry
First posted
Aug 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate whether budesonide/formoterol powder for inhalation (II) manufactured by Shanghai New Huanghe Pharmaceutical Co., Ltd. is non-inferior to the active comparator, Symbicort® Turbuhaler® (AstraZeneca), in the treatment of adult bronchial asthma, and to assess its safety profile in this population. The main questions it aims to answer are: Does the test product (budesonide/formoterol 160 μg/4.5 μg) show non-inferior efficacy compared to the reference product (Symbicort® Turbuhaler® 160 μg/4.5 μg) in improving lung function, as measured by the change from baseline in trough FEV1 after 42 days of treatment? What is the safety profile of the test product in adult patients with asthma? Researchers will compare participants receiving the test product plus placebo of the comparator to those receiving the active comparator plus placebo of the test product, to see if the test product is non-inferior to the reference product in terms of efficacy, with comparable safety. Participants will: Be randomized to receive either the test product (budesonide/formoterol 160 μg/4.5 μg, 2 inhalations twice daily) plus placebo of the comparator, or the active comparator (Symbicort® Turbuhaler® 160 μg/4.5 μg, 2 inhalations twice daily) plus placebo of the test product, for 6 weeks of treatment Perform daily morning and evening PEF measurements and record them, along with rescue medication use and any adverse events, in a diary card Attend regular clinic visits for pulmonary function tests, ACQ-5 and AQLQ questionnaires, safety assessments (vital signs, physical and oropharyngeal examinations, laboratory tests, and 12-lead ECG), and drug accountability

Conditions

  • Asthma

Interventions

  • Budesonide and Formoterol FumarateDrug

    Budesonide/formoterol 160 μg/4.5 μg per inhalation, administered as 2 inhalations twice daily via the Pingchuan® dry powder inhaler.

  • Placebo of Budesonide and Formoterol FumarateDrug

    Placebo matching the test product, containing inactive excipients only, administered as 2 inhalations twice daily via the Pingchuan® dry powder inhaler.

  • Budesonide and Formoterol FumarateDrug

    Active comparator: Symbicort® Turbuhaler® (budesonide/formoterol 160 μg/4.5 μg per inhalation), administered as 2 inhalations twice daily via the Turbuhaler® dry powder inhaler. Manufactured by AstraZeneca.

  • Placebo of Budesonide and Formoterol FumarateDrug

    Placebo matching the active comparator (Symbicort® Turbuhaler®), containing inactive excipients only, administered as 2 inhalations twice daily via the Turbuhaler® dry powder inhaler.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in trough FEV1 after 42 days of treatmentTime frame: Baseline (Day 1 pre-dose) to Day 43

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • Hefei First People's Hospital

    Hefei, Anhui, China

  • Beijing Chao-Yang Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, China

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

  • The Second Affiliated Hospital of Xiamen Medical College

    Xiamen, Fujian, China

  • Gansu Provincial People's Hospital

    Lanzhou, Gansu, China

  • Huizhou Central People's Hospital

    Huizhou, Guangdong, China

  • Guangzhou Medical University Affiliated Qingyuan Hospital (Qingyuan People's Hospital)

    Qingyuan, Guangdong, China

  • Zhanjiang Central People's Hospital

    Zhanjiang, Guangdong, China

  • Affiliated Hospital of Zunyi Medical University

    Zunyi, Guizhou, China

  • Harrison International Peace Hospital

    Hengshui, Hebei, China

  • Hebei PetroChina Central Hospital

    Langfang, Hebei, China

  • Daqing People's Hospital

    Daqing, Heilongjiang, China

  • Yellow River Sanmenxia Hospital

    Sanmenxia, Henan, China

  • The First Affiliated Hospital of Xinxiang Medical University

    Xinxiang, Henan, China

  • Yueyang Central Hospital

    Yueyang, Hunan, China

  • The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology

    Baotou, Inner Mongolia, China

  • Baotou Central Hospital

    Baotou, Inner Mongolia, China

  • Affiliated Hospital of Inner Mongolia Medical University

    Hohhot, Inner Mongolia, China

  • Northern Jiangsu People's Hospital

    Yangzhou, Jiangsu, China

  • The First Affiliated Hospital of Gannan Medical University

    Ganzhou, Jiangxi, China

  • Central Hospital Affiliated to Shenyang Medical College

    Shenyang, Liaoning, China

  • Jinan Central Hospital

    Jinan, Shandong, China

  • Jining First People's Hospital

    Jining, Shandong, China

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China

  • Mianyang Central Hospital

    Mianyang, Sichuan, China

  • Tianjin Fourth Central Hospital

    Tianjin, Tianjin Municipality, China

  • Lishui Central Hospital

    Lishui, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.